Actively Recruiting
Understanding and Tailored Treatment of Low Anterior Resection Syndrome
Led by Aalborg University Hospital · Updated on 2026-05-07
145
Participants Needed
3
Research Sites
119 weeks
Total Duration
On this page
Sponsors
A
Aalborg University Hospital
Lead Sponsor
A
Aarhus University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to learn why some patients develop low anterior resection syndrome (LARS) after colorectal cancer treatment. The study also aims to identify different subtypes of LARS and understand which patients may respond to specific treatments. The main questions it aims to answer are: * What physiological and imaging changes are associated with LARS? * How do patients with LARS differ from patients without LARS after colorectal cancer surgery? * Are there measurable differences between LARS, patients treated with organ-preserving chemoradiotherapy, and patients with fecal incontinence? Participants will: * Complete advanced physiological and imaging assessments related to bowel function * Be compared with four control groups: * patients without LARS after colorectal cancer surgery * patients treated with organ-preserving chemoradiotherapy * patients with fecal incontinence and urge fecal incontinence * Take part in a single study visit where all measurements are performed
CONDITIONS
Official Title
Understanding and Tailored Treatment of Low Anterior Resection Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be able to read and understand Danish.
- Adults older than 18 years with full legal capacity.
- Able to understand the research protocol, comply with procedures, attend hospital visits, and complete the trial.
- Patients with rectal cancer operated with rectal resection and sphincter preserving surgery at least 3 months after surgery.
- If having a temporary protective ileostomy, it must have been reversed for at least 3 months.
- Patients planned for neuromodulation with satisfactory test results leading to permanent pacemaker implantation for sacral nerve modulation.
- Rectum/colon cancer patients treated with organ-preserving chemoradiotherapy showing complete response at least 12 months posttreatment.
You will not qualify if you...
- Unable to understand information.
- Connective tissue disorders.
- Parkinson's disease.
- Non-MRI compatible pacemaker, clips, or metal objects (patients with sacral nerve modulation pacemaker will not have postoperative MRI).
- Non-removable piercings before MRI.
- Claustrophobia.
- Latex allergy.
- Abdominal diameter 140 cm or more.
- Any other physician-determined contraindications.
- Participation in another clinical trial.
- Known intestinal obstruction, significant strictures, or perforation.
- Disorders of swallowing.
- Pregnant women.
- History of anastomotic leakage after rectal resection surgery.
- Evidence of local cancer recurrence or spread.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Aalborg University Hospital
Aalborg, Denmark, 9220
Active, Not Recruiting
2
Aarhus University Hospital
Aarhus, Denmark, 8200
Actively Recruiting
3
Vejle Hospital
Vejle, Denmark, 7100
Actively Recruiting
Research Team
E
Esben B Mark, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here